BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24239188)

  • 1. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
    Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
    Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
    J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
    Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
    Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
    Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N
    Woodward HL; Innocenti P; Cheung KJ; Hayes A; Roberts J; Henley AT; Faisal A; Mak GW; Box G; Westwood IM; Cronin N; Carter M; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Burke R; Broccatelli F; van Montfort RLM; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S
    J Med Chem; 2018 Sep; 61(18):8226-8240. PubMed ID: 30199249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
    Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
    Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
    Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
    Weber C; Sipos M; Paczal A; Balint B; Kun V; Foloppe N; Dokurno P; Massey AJ; Walmsley DL; Hubbard RE; Murray J; Benwell K; Edmonds T; Demarles D; Bruno A; Burbridge M; Cruzalegui F; Kotschy A
    J Med Chem; 2021 May; 64(10):6745-6764. PubMed ID: 33975430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of Interaction Mechanism between Pyrido [3,4-
    Xing C; Zhou X; Chen C; Sun W; Zheng Q; Liang D
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.